Anzeige
Meldung des Tages: Golden Cross bestätigt ein Fosterville-ähnliches System — und jetzt wird tiefer gebohrt

Cambiar Aggressive Value ETF News

ETF
WKN:  ISIN:  US0075W01639 US-Symbol:  CAMX
29,766 €
+0,00 $
0,00%
29,766 € 11.02.26
Depot/Watchlist
Indexbildung
Ertragsverwendung
-
Lfd. Kosten
-
Fondsgröße
-  
Tracking Error
-
Währung
FWW Fundstars
keine Bewertung

Cambiar Aggressive Value ETF News

09.01.26 - PR Newswire
Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly
Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly PR Newswire
09.01.26 - PR Newswire
Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly
Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly PR Newswire
10.11.25 - PR Newswire
Camurus reports positive topline results for CAM2056, semaglutide monthly depot
Camurus reports positive topline results for CAM2056, semaglutide monthly depot PR Newswire
10.11.25 - PR Newswire
Camurus reports positive topline results for CAM2056, semaglutide monthly depot
Camurus reports positive topline results for CAM2056, semaglutide monthly depot PR Newswire
28.08.25 - PR Newswire
Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK
Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK PR Newswire
01.07.25 - PR Newswire
Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU
Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU PR Newswire
01.07.25 - PR Newswire
Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU
Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU PR Newswire
18.06.25 - PR Newswire
Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients
Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients PR Newswire
18.06.25 - PR Newswire
Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients
Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients PR Newswire
03.06.25 - PR Newswire
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
Camurus and Lilly enter collaboration and license agreement for long-​acting FluidCrystal® incretins PR Newswire
03.06.25 - PR Newswire
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
Camurus and Lilly enter collaboration and license agreement for long-​acting FluidCrystal® incretins PR Newswire
25.04.25 - PR Newswire
CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU
CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU PR Newswire
25.04.25 - PR Newswire
CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU
CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU PR Newswire

Newssuche

Videos

newspaper
03.04.26
RW QUANTUM Strategie Einführung
Am Sonntag, den 12.4.26 wird erstmals die RW QUANTUM Strategie geschult. Der Ansatz handelt die ... Mehr »